Clinical Trials Browser

NCT05564377 2026-05-27

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05472792 2026-05-26

CAMERAN

Phase 2 Recruiting

90 enrolled

Breast

Breast Neoplasms

NCT07117630 2026-05-19

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms

NCT06428396 2026-05-18

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT06979596 2026-05-13

OMAHA-015

Phase 2 Recruiting

250 enrolled

Tumor-Agnostic

Neoplasms

NCT07368998 2026-05-11

optINAVO

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

484 enrolled

Breast

Breast Neoplasms

NCT04606446 2026-04-16

KAT6

Phase 2 Recruiting

320 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

200 enrolled

Breast

Locoregional Recurrence

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT07498478 2026-03-27

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Phase 2 Recruiting

94 enrolled

Breast

Breast Neoplasms

NCT05524584 2026-03-11

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT06494150 2026-02-23

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Phase 2 Recruiting

37 enrolled

Gynecologic

Ovarian Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Phase 2 Recruiting

28 enrolled

Breast

ER-Positive Breast Cancer

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Phase 2 Recruiting

118 enrolled

Breast

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

15 enrolled

Breast

Breast Neoplasms

NCT07180160 2025-11-18

ITHRAN

Phase 2 Recruiting

123 enrolled

Breast

Advanced Breast Cancer

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

70 enrolled

Breast

Breast Neoplasms

NCT05113368 2025-08-21

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Phase 2 Recruiting

31 enrolled

Gynecologic

Ovarian Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Phase 2 Recruiting

50 enrolled

Breast

Breast Neoplasms

NCT05181033 2025-07-25

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT05536128 2025-04-17

Post-CDK

Phase 2 Recruiting

64 enrolled

Breast

Advanced Breast Cancer

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

NCT05816655 2025-03-18

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Recruiting

202 enrolled

Breast

Breast Neoplasms

NCT04985266 2024-12-05

TRAK-ER

Phase 2 Recruiting

1,100 enrolled

Breast

ER+ Breast Cancer

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

620 enrolled

Breast

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasm Female